Salman Fazal, Hematology Lead at UPMC Hillman Cancer Center, shared on LinkedIn:
“Any discussions about bispecific antibodies in community practice focus on whether they can be administered outside major academic centers.
The more important question is:
How do you actually implement them?
When developing a bispecific program in the community, some of the most valuable lessons come from centers with similar resources, staffing models, and operational challenges.
Innovation gets therapies approved. Implementation gets them to patients. The future of bispecific therapy depends not only on scientific advances, but also on practical strategies that allow patients to access these treatments closer to home.”
Other articles featuring Salman Fazal on OncoDaily.